Publications

Debio 0123, A Selective WEE1 Inhibitor in Clinical Development for Patients with Solid Tumors

Safety assessment of DPI-4452, a cyclic peptide targeting Carbonic Anhydrase IX

Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse Large B Cell Lymphoma…

Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase 1 clinical trial

Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression…

AbYlink™: A template mediated regio-selective labeling method for preclinical imaging of therapeutic antibodies

Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma

[177Lu]Lu-DPI-4452 & [68Ga]Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models